Clarence De Belilovsky 1, Elia Roo-Rodriguez 2, Caroline Baudouin 3, Franck Menu 3, Bernard Chadoutaud 4 & Philippe Msika 3
1 Department of Dermatology, Institut Alfred Fournier, Paris, France
2 Department of Dermatology, Hospital Sur, Alcorcon, Madrid, Spain
3 Laboratoires Expanscience, Innovation Research and Development Direction, Epernon, France
4 ClinReal Online, Toulouse, France
Atopic dermatitis (AD) requires permanent skin care.
A cream containing 2% SO (sunflower oleodistillate), with peroxisome proliferator-activated receptor-alpha (PPAR-α) agonist properties, has been compared to a topical steroid (hydrocortisone butyro-propionate 1 mg/g).
An open, randomized study included two groups of 40 children (aged 3 months to 4 years).
Group A applied the steroid and group B applied the 2% SO cream, twice a day.
SCORAD (SCORing Atopic Dermatitis) was determined at D0, D7 and D21 and quality of life (QoL) at D0 and D21.
SCORAD was similar at D0 (37.2 versus 36.9), D7 (18.9 versus 19.2) (–49% and –48%) and D21 (11 versus 9.4) (–70% and –75%) (p < 0.01 versus D0).
The Infant Dermatitis Quality of Life and Dermatitis Family Impact Questionnaire improved similarly by 65%/67% in group A and 72%/75% in group B at D21 (p < 0.01 versus D0).
A 2% SO cream has demonstrated therapeutic properties, using clinical scores and QoL, comparable to those of a topical steroid.
1 Laboratoires Dermatologiques d’Uriage, Paris, France
2 ClinReal Online, Toulouse, France